1 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 MutationLocally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 MutationRecruitingPhase 1 / Phase 22026-05-11NCT06501625